$25.36
Insights on Xoma Corp
Revenue is up for the last 2 quarters, 830.0K → 1.83M (in $), with an average increase of 54.7% per quarter
Netprofit is down for the last 3 quarters, -5.4M → -20.10M (in $), with an average decrease of 133.5% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 19.4%
In the last 3 years, Novo Nordisk A/s has given 240.5% return, outperforming this stock by 272.5%
0.63%
Downside
Day's Volatility :5.79%
Upside
5.2%
46.85%
Downside
52 Weeks Volatility :50.07%
Upside
6.07%
Period | Xoma Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 26.99% | 1.1% | 0.0% |
6 Months | 45.85% | 12.5% | 0.0% |
1 Year | 33.54% | 6.9% | 2.2% |
3 Years | -32.01% | 14.3% | -23.0% |
Market Capitalization | 303.6M |
Book Value | $7.71 |
Earnings Per Share (EPS) | -4.04 |
PEG Ratio | -0.42 |
Wall Street Target Price | 74.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -309.93% |
Return On Assets TTM | -7.3% |
Return On Equity TTM | -38.39% |
Revenue TTM | 4.8M |
Revenue Per Share TTM | 0.42 |
Quarterly Revenue Growth YOY | 23.400000000000002% |
Gross Profit TTM | 5.9M |
EBITDA | -21.0M |
Diluted Eps TTM | -4.04 |
Quarterly Earnings Growth YOY | 0.37 |
EPS Estimate Current Year | -2.14 |
EPS Estimate Next Year | -1.7 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.58 |
What analysts predicted
Upside of 191.8%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 5.3M | ↓ 89.94% |
Net Income | -13.3M | ↓ 191.42% |
Net Profit Margin | -251.8% | ↓ 279.5% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 18.4M | ↑ 246.67% |
Net Income | -7.7M | ↓ 42.31% |
Net Profit Margin | -41.91% | ↑ 209.89% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 29.4M | ↑ 59.96% |
Net Income | 13.3M | ↓ 272.75% |
Net Profit Margin | 45.25% | ↑ 87.16% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 38.2M | ↑ 29.86% |
Net Income | 15.8M | ↑ 18.8% |
Net Profit Margin | 41.4% | ↓ 3.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.0M | ↓ 84.21% |
Net Income | -17.1M | ↓ 208.27% |
Net Profit Margin | -283.79% | ↓ 325.19% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.8M | ↓ 21.06% |
Net Income | -40.8M | ↑ 138.72% |
Net Profit Margin | -858.15% | ↓ 574.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 451.0K | ↓ 54.12% |
Net Income | -4.0M | ↓ 13.62% |
Net Profit Margin | -883.37% | ↓ 414.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.5M | ↑ 229.49% |
Net Income | -6.0M | ↑ 50.0% |
Net Profit Margin | -402.15% | ↑ 481.22% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 437.0K | ↓ 70.59% |
Net Income | -17.7M | ↑ 196.52% |
Net Profit Margin | -4.1K% | ↓ 3652.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7M | ↑ 279.41% |
Net Income | -5.4M | ↓ 69.53% |
Net Profit Margin | -325.69% | ↑ 3729.23% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 830.0K | ↓ 49.94% |
Net Income | -5.5M | ↑ 2.02% |
Net Profit Margin | -663.73% | ↓ 338.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8M | ↑ 120.84% |
Net Income | -20.1M | ↑ 265.02% |
Net Profit Margin | -1.1K% | ↓ 433.32% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 63.8M | ↑ 41.95% |
Total Liabilities | 45.0M | ↑ 14.95% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 95.7M | ↑ 50.07% |
Total Liabilities | 51.7M | ↑ 14.97% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 125.3M | ↑ 30.88% |
Total Liabilities | 38.9M | ↓ 24.89% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 166.6M | ↑ 32.95% |
Total Liabilities | 24.7M | ↓ 36.48% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 140.4M | ↓ 15.72% |
Total Liabilities | 16.4M | ↓ 33.7% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 234.3M | ↑ 66.9% |
Total Liabilities | 145.6M | ↑ 789.42% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 146.1M | ↓ 5.25% |
Total Liabilities | 15.8M | ↓ 17.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 140.4M | ↓ 3.93% |
Total Liabilities | 16.4M | ↑ 3.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 133.7M | ↓ 4.79% |
Total Liabilities | 19.1M | ↑ 16.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 125.7M | ↓ 5.99% |
Total Liabilities | 15.5M | ↓ 18.82% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 124.1M | ↓ 1.25% |
Total Liabilities | 18.1M | ↑ 16.69% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 234.3M | ↑ 88.81% |
Total Liabilities | 145.6M | ↑ 702.98% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.6M | ↓ 570.74% |
Investing Cash Flow | -15.0M | ↓ 1034.37% |
Financing Cash Flow | 29.9M | ↑ 125.82% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -285.0K | ↓ 97.75% |
Investing Cash Flow | -19.3M | ↑ 28.62% |
Financing Cash Flow | 30.5M | ↑ 1.85% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.1M | ↓ 3641.05% |
Investing Cash Flow | -209.0K | ↓ 98.92% |
Financing Cash Flow | 19.8M | ↓ 35.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 22.7M | ↑ 124.71% |
Investing Cash Flow | -26.5M | ↑ 12579.43% |
Financing Cash Flow | 12.8M | ↓ 35.15% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.9M | ↓ 156.79% |
Investing Cash Flow | -20.2M | ↓ 23.69% |
Financing Cash Flow | -4.5M | ↓ 134.68% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 15.15% |
Investing Cash Flow | 26.0K | ↑ 0.0% |
Financing Cash Flow | -1.3M | ↑ 11.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.9M | ↑ 6.2% |
Investing Cash Flow | -15.2M | ↓ 58742.31% |
Financing Cash Flow | -1.3M | ↑ 4.92% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↑ 26.58% |
Investing Cash Flow | -7.2M | ↓ 52.55% |
Financing Cash Flow | -1.4M | ↑ 3.48% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.2M | ↑ 46.39% |
Investing Cash Flow | -4.5M | ↓ 38.04% |
Financing Cash Flow | -1.2M | ↓ 14.84% |
Sell
Neutral
Buy
Xoma Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Xoma Corp | 10.76% | 45.85% | 33.54% | -32.01% | 111.38% |
Moderna, Inc. | 1.34% | 41.81% | -16.73% | -38.71% | 314.51% |
Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
Vertex Pharmaceuticals Incorporated | -4.23% | 10.39% | 23.96% | 84.71% | 131.85% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Xoma Corp | 24.2 | NA | -0.42 | -2.14 | -0.38 | -0.07 | NA | 7.71 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Xoma Corp | Buy | $303.6M | 111.38% | 24.2 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 314.51% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 131.85% | 29.17 | 36.68% |
Bvf Inc
FMR Inc
BlackRock Inc
Vanguard Group Inc
Opaleye Management Inc
Stonepine Capital Management Llc
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
Organization | Xoma Corp |
Employees | 13 |
CEO | Mr. Owen P. Hughes Jr. |
Industry | Health Technology |